BHCM
NBIX icon

Brevan Howard Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Brevan Howard Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,723
Closed -$1.41M – 2411
2026
Q1 		$1.41M Buy
10,723
+9,242
+624% +$1.23M 0.01% 724
2025
Q4 		$210K Sell
1,481
-2,403
-62% -$348K ﹤0.01% 1555
2025
Q3 		$545K Sell
3,884
-11,752
-75% -$1.59M ﹤0.01% 1251
2025
Q2 		$1.97M Buy
+15,636
New +$1.79M 0.01% 745
2025
Q1 		– Sell
-6,600
Closed -$901K – 1354
2024
Q4 		$901K Buy
6,600
+507
+8% +$62.7K 0.01% 458
2024
Q3 		$702K Buy
6,093
+2,109
+53% +$289K ﹤0.01% 578
2024
Q2 		$548K Sell
3,984
-2,146
-35% -$294K ﹤0.01% 574
2024
Q1 		$845K Buy
6,130
+624
+11% +$85.2K 0.01% 313
2023
Q4 		$725K Buy
5,506
+3,551
+182% +$409K 0.01% 347
2023
Q3 		$220K Buy
+1,955
New +$206K ﹤0.01% 308

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brevan Howard Capital Management's NBIX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 10,723 shares — an estimated $1.41M sold.

Brevan Howard Capital Management first reported a position in NBIX in Q3 2023 and held it in 10 quarters. The position peaked at $1.97M in Q2 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,723 Neurocrine Biosciences shares in Q2 2026, an estimated $1.41M.
  • Brevan Howard Capital Management first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 10 quarters.
  • Brevan Howard Capital Management's Neurocrine Biosciences position peaked at $1.97M in Q2 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.